We provide you with 20 years of free, institutional-grade data for FNCH stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FNCH. Explore the full financial landscape of FNCH stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| SMISEK JEFFERY A | Sale | -1,600 | $2.61 | $4,176 | 2024-03-29 |
| SMISEK JEFFERY A | Sale | -6,642 | $2.57 | $17,070 | 2024-03-29 |
| SMISEK JEFFERY A | Sale | -1,470 | $3.64 | $5,351 | 2023-11-27 |
| Graf Susan E | Open Market Purchase | 5,010 | $0.27 | 2023-06-09 | |
| Blaustein Marc | Sale | -4,619 | $0.38 | $1,755 | 2023-02-23 |
| Blaustein Marc | Sale | -3,636 | $1.39 | $5,054 | 2022-10-25 |
| Vittiglio Joseph | Sale | -3,636 | $1.39 | $5,054 | 2022-10-25 |
| Vittiglio Joseph | Grant, award...etc | 35,000 | 2022-06-15 | ||
| Blaustein Marc | Grant, award...etc | 35,000 | 2022-06-15 | ||
| Haft Nicholas | Open Market Purchase | 63,850 | $10.18 | 2021-12-22 | |
| Crestovo Investor LLC | Open Market Purchase | 735,294 | $17 | 2021-03-25 | |
| SMISEK JEFFERY A | Open Market Purchase | 88,235 | $17 | 2021-03-25 | |
| Haft Nicholas | Open Market Purchase | 882,351 | $17 | 2021-03-25 | |
| FERRANTE DOMENIC J | Open Market Purchase | 102,941 | $17 | 2021-03-25 | |
| Smith Mark Burnham | Initial | 2021-03-18 | |||
| Kassam Zain | Initial | 2021-03-18 |
The information provided in this report about FNCH stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Finch Therapeutics Group, Inc(NASDAQ:FNCH) 
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the t...
Share this website to your friends